Cargando…
Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries
Schizophrenia-spectrum disorders are associated with substantial impairment and disability. Lack of treatment adherence is a major issue, especially in low- and middle-income countries (LMICs). Despite growing evidence supporting second-generation long-acting antipsychotics (LAIs) as an effective st...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121849/ https://www.ncbi.nlm.nih.gov/pubmed/35543395 http://dx.doi.org/10.1017/S2045796022000166 |
_version_ | 1784711229421387776 |
---|---|
author | Ostuzzi, Giovanni Gastaldon, Chiara Papola, Davide Barbui, Corrado |
author_facet | Ostuzzi, Giovanni Gastaldon, Chiara Papola, Davide Barbui, Corrado |
author_sort | Ostuzzi, Giovanni |
collection | PubMed |
description | Schizophrenia-spectrum disorders are associated with substantial impairment and disability. Lack of treatment adherence is a major issue, especially in low- and middle-income countries (LMICs). Despite growing evidence supporting second-generation long-acting antipsychotics (LAIs) as an effective strategy to ensure continued maintenance treatment in schizophrenia, access to these technologies has been very limited in constrained-resource settings. Including second-generation LAIs in national and international essential medicines lists and evidence-based guidelines, promoting public health-oriented patent pooling and extending their availability to primary health care settings, are key actions that should urgently be implemented to increase access to long-acting technologies. Implementing these policy actions can pragmatically improve treatment adherence, ultimately tackling schizophrenia-related impairment and disability in LMICs, which can be regarded as a global health priority. |
format | Online Article Text |
id | pubmed-9121849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91218492022-06-01 Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries Ostuzzi, Giovanni Gastaldon, Chiara Papola, Davide Barbui, Corrado Epidemiol Psychiatr Sci Editorial Schizophrenia-spectrum disorders are associated with substantial impairment and disability. Lack of treatment adherence is a major issue, especially in low- and middle-income countries (LMICs). Despite growing evidence supporting second-generation long-acting antipsychotics (LAIs) as an effective strategy to ensure continued maintenance treatment in schizophrenia, access to these technologies has been very limited in constrained-resource settings. Including second-generation LAIs in national and international essential medicines lists and evidence-based guidelines, promoting public health-oriented patent pooling and extending their availability to primary health care settings, are key actions that should urgently be implemented to increase access to long-acting technologies. Implementing these policy actions can pragmatically improve treatment adherence, ultimately tackling schizophrenia-related impairment and disability in LMICs, which can be regarded as a global health priority. Cambridge University Press 2022-05-11 /pmc/articles/PMC9121849/ /pubmed/35543395 http://dx.doi.org/10.1017/S2045796022000166 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited. |
spellingShingle | Editorial Ostuzzi, Giovanni Gastaldon, Chiara Papola, Davide Barbui, Corrado Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries |
title | Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries |
title_full | Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries |
title_fullStr | Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries |
title_full_unstemmed | Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries |
title_short | Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries |
title_sort | calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121849/ https://www.ncbi.nlm.nih.gov/pubmed/35543395 http://dx.doi.org/10.1017/S2045796022000166 |
work_keys_str_mv | AT ostuzzigiovanni callingforpolicyactionstoincreaseaccesstolongactingantipsychoticsinlowincomeandmiddleincomecountries AT gastaldonchiara callingforpolicyactionstoincreaseaccesstolongactingantipsychoticsinlowincomeandmiddleincomecountries AT papoladavide callingforpolicyactionstoincreaseaccesstolongactingantipsychoticsinlowincomeandmiddleincomecountries AT barbuicorrado callingforpolicyactionstoincreaseaccesstolongactingantipsychoticsinlowincomeandmiddleincomecountries |